Hangzhou Diagens Biotechnology (HKG:2526) entered into a three-year strategic cooperation agreement with Yongjiang Laboratory, a Friday bourse filing showed.
Under the contract, the parties will jointly promote the training, optimization, validation, and demonstration application of large-scale models for medical imaging in Guangxi.
Yongjiang Laboratory is a key digital intelligence innovation platform developed by the Guangxi Zhuang Autonomous Region.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.